eyal ballan

warning: Creating default object from empty value in /home/hemporg/public_html/news/modules/taxonomy/taxonomy.pages.inc on line 34.

Colorado: 'First Ever' Extended Release Cannabis Capsule Released


Wana Products on Tuesday announced the launch of WanaCaps XR, a family of extended release cannabis capsules that provide medicinal benefits for up to 12 hours.

Wana Products partnered with Cannabics Pharmaceuticals Inc., a United States-based Drug Development Company with research and development in Israel, that developed the proprietary technology behind the extended release formulation.

WanaCaps XR will be offered in three different formulations: capsules with a 10:1 CBD to THC ratio (WanaCaps XR High CBD Capsules), a 10:1 THC to CBD ratio (WanaCaps XR High THC Capsules), and a balanced formulation with 1:1 THC:CBD ratio (WanaCaps XR THC/CBD Balanced Capsules).

“WanaCaps XR represents the next generation in the evolution of marijuana for the medical community,” said Nancy Whiteman, co-owner of Wana Products. “The extended release formulation enables patients to dose once or twice daily so they can get on with their lives without the constant need to be thinking about re-dosing. Additionally, WanaCaps XR are formulated to be highly bio-available so patients feel the therapeutic impact quickly.”

“The new capsules also address one of the major concerns of cannabis patients, which is that the initial high peak of cannabinoid activity soon after administration which can cause uncomfortable side effects such as disorientation and dizziness,” Whiteman said. “Instead, with WanaCaps XR, patients experience a long-lasting, stable effect for up to 10 hours without the ups and downs. Overall, it’s just a much better experience for patients.”

U.S.: Company Files Patent Application For Personalized Cannabis Anti-Cancer Treatment


A U.S.-based company on Thursday announced that it has filed an exclusive patent application with the United States Patent & Trademark Office on a system designed give personalized anti-tumor treatments to cancer patients using cannabinoid therapy.

Cannabics Pharmaceuticals Inc. (CNBX) announced announced the patent application on "a System and Method for High Throughput Screening of Cancer Cells."

In this proprietary system, biopsies are treated, in-vitro, with numerous plant extract combinations and the anti-tumor effects are screened and calculated. The results could enable cancer patients to receive cannabinoid based therapy with a potential of reducing their tumors, according to the company.

Cannabics Pharmaceuticals announced it plans to complete the development of this novel and sophisticated technology and license it by the end of 2016.

"Cannabinoids are known for their anti-tumor properties, and this natural personalized therapy could be highly effective and without side effects, thus benefiting millions of patients worldwide," said Dr. Eyal Ballan, chief scientist of the company.

Syndicate content